Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ORKA with free AI briefings, catalyst countdowns, and dilution alerts.

ORKA · Oruka Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
93.4mo Cash Runway
Follow ORKA by email Get an email when ORKA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ORKA, unsubscribe in one click. Privacy

📣 What ORKA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ORKA-001 Plaque Psoriasis Phase 2 · NCT07449702 Recruiting
ORKA-001 Induction Dose Plaque Psoriasis Phase 2 · NCT07090330 Active not recruiting
ORKA-001 Maintenance Dose Plaque Psoriasis Phase 2 · NCT07090330 Active not recruiting
ORKA-002 Plaque Psoriasis Phase 2 · NCT07474792 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ORKA holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $38.7M/quarter from operations, an estimated runway of 93.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORKA files for a raise →

👥 Who Owns ORKA

Insiders 7.5% Other 5%+ holders 28.2% Institutions (358 holders) 64.3% Public and other holders 0%
HolderTypeShares% of sharesAs of
Harwin Peter Evan 5%+ holder (13D) 14,572,917 21.49% 2026-07-01
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 4,556,952 6.72% 2026-06-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 4,392,166 6.48% 2026-09-30
Fairmount Funds Management LLC
Director, 10% owner · +103,633 options
Insider 3,705,262 5.46% 2026-07-01
Capital World Investors Institution (13G, 5%+) 3,401,639 5.02% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 3,175,483 4.68% 2025-12-31
Lawrence Otto Klein
Chief Executive Officer, Director · +1.50M options
Insider 923,128 1.36% 2026-11-02
Laura Lee Sandler
Chief Operating Officer · +74,996 options
Insider 235,478 0.35% 2026-09-15
Larry Todd Edwards
Chief Commercial Officer · +20,000 options
Insider 100,000 0.15% 2026-08-24
Carl Dambkowski
Director · +58,658 options
Insider 38,743 0.06% 2026-06-11
Joana Goncalves
Chief Medical Officer · +344,555 options
Insider 31,771 0.05% 2026-11-16
Paul T Quinlan
General Counsel · +191,496 options
Insider 29,995 0.04% 2026-10-20

Share count 67,822,359 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ORKA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORKA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.